“Shift Toward Biologic and Targeted Immunomodulatory Therapies”
- A prominent trend in the Uveitis Drug Market is the increasing adoption of biologic agents and targeted therapies, particularly in non-infectious uveitis cases that are refractory to conventional corticosteroids.Treatments now increasingly focus on TNF-alpha inhibitors, IL-6 antagonists, and T-cell modulators to address the underlying immune pathways with greater specificity.
- For instance, adalimumab, a TNF-alpha inhibitor, has been FDA-approved for non-infectious intermediate, posterior, and panuveitis, offering sustained remission and reduced flare-ups.
- The integration of OCT imaging, AI-based diagnostics, and personalized dosing algorithms is enhancing the precision of disease monitoring and treatment adjustment.
- Additionally, the development of depot injections and ocular implants delivering sustained drug release is improving patient compliance and reducing systemic side effects.
